A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK

Journal of Medical Economics

Volumn 14, Issue 5, 2011, Pages 584-593

  Lowin, Julia ^a   Bergman, Annika ^b   Ray Chaudhuri, K ^c   Findley, Leslie J ^d   Roeder, Claudia ^a   Schifflers, Mathias ^e   Wood, Eifiona ^a   Morris, Stephen ^f  

^a IQVIA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d QUEEN S HOSPITAL   (United Kingdom)

^e Abbott Healthcare Products Ltd   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced Parkinson's disease; Cost effectiveness; Incremental cost effectiveness ratio (ICER); Levodopa carbidopa intestinal gel; Off time; Quality adjusted life years (QALY)

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADVANCED PARKINSON DISEASE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DOPAMINERGIC ACTIVITY; GEL; HEALTH CARE COST; HEALTH STATUS; HUMAN; LONG TERM CARE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; STANDARD; TREATMENT RESPONSE; UNCERTAINTY; UNITED KINGDOM;

ANTIPARKINSON AGENTS; CARBIDOPA; COST-BENEFIT ANALYSIS; GELS; GREAT BRITAIN; HUMANS; LEVODOPA; PARKINSON DISEASE; QUALITY-ADJUSTED LIFE YEARS;

EID: 80052729549     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.598201     Document Type: Review

References (37)

1. Dewey Jr RB. Management of motor complications in Parkinson's disease. Neurology 2004;62:S3-7
2. Factors impacting on quality of life in Parkinson's disease: Results from an international survey. Mov Disord 2002;17:60-7
3. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord 1998;13:406-13
4. Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9:163-8
5. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-18
6. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson's disease: The spouse's perspective by stage of disease. Mov Disord 1998;13:20-8
7. Martinez-Martin P, ito-Leon J, Alonso F, et al. Quality of life of caregivers in Parkinson's disease. Qual Life Res 2005;14:436-72
8. Martinez-Martin P, Forjaz MJ, Frades-Payo B, et al. Caregiver burden in Parkinson's disease. Mov Disord 2007;22:924-31
9. Martinez-Martin P, Arroyo S, Rojo-Abuin JM, et al. Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. Mov Disord 2008;23:1673-80
10. National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians, 2006. Report No.: CG35
11. Department of Health & Human Services. Levodopa/carbidopa as orphan drug, application #99-1294, 2000
12. European Commission-Enterprise and Industry Directorate General-Consumer goods-Pharmaceuticals. Levodopa and Carbidopa (Gastroenteral use) EU Orphan Designation number: EU3/01/035. 2008. Available http://ec.europa.eu/health/ documents/community-register/html/o035.htm (Last accessed 8 December 2011
13. Department of Health of Ageing Therapeutic Goods Administration (2006). Duodopa (levodopa 20 mg/mL and carbidopa 5 mg/mL) intestinal gel suspension-Orphan Drug Application, Submission No. 2006/0636/1. 2006
14. Department of Health, Labor and Welfare. Designation number 224. 2009
15. European Commission. The Orphan Drugs Strategy. 2007
16. Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42
17. Frankel J. Verification of epidemiological and clinical assumptions for Duodopa Budget Impact Model. 2006 (personal communication
18. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: A community based study. Brain 2000;123:2297-305
19. Findley L, Wood E, Lowin J, et al. The economic burden of advanced Parkinson's disease: An analysis of a UK patient dataset. J Med Econ 2011;14:130-9
20. Willis M, Persson U, Zoellner Y, et al. Reducing uncertainty in value-based pricing using evidence development agreements. The case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa) in Sweden. Applied Health Economics & Health Policy 2010;8:1-10
21. Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: A decision-analytic model. Value Health 2001;4:308-15
22. Palmer CS, Schmier JK, Snyder E, et al. Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. Qual Life Res 2000;9:819-27
23. Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002;20:617-28
24. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
25. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: Practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
26. Neville A, Parson R, Nyhom D. Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage. Submitted 2011
27. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001; 104:343-8
28. Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: Long-term exposure. Clin Neuropharmacol 2008;31:63-73
29. Nyholm D, Remahl N, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson's disease. Neurology. 2005 Jan 25;64(2):216-23
30. Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes-a means to understand. Curr Med Res Opin 2008 Nov;24(11):3063-72
31. Valldeoriola F, Morsi O, Tolosa E, et al. Prospective comparative study on costeffectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-91
32. National Institute for Health and Clinical Excellence. Appraising Orphan Drugs (Draft 3). Available at: Http://www.nice.org.uk/niceMedia/pdf/smt/ 120705item4.pdf [Last accessed 13 December 2010]
33. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: Should we value rarity? BMJ 2005;331:1016-19
34. Department of Health. NHS Reference Costs Appendix NSRC04 NHS Trust and PCT Combined Reference Cost Schedules. Available at: Http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH-098945 (Last accessed 13 December 2010
35. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
36. Curtis L. Unit Costs of Health and Social Care. Personal Social Services Research Unit, University of Kent. 2008. Available at: Http://www.pssru.ac.uk/ uc/uc2008contents.htm (Last accessed 15 December 2010
37. Joint Formulary Committee. British National Formulary [57]. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009